patients, only 14 had electrophysiologic data consistent with the Guillain-Barre syndrome and therefore could have met Brighton level 1 diagnostic criteria for the syndrome. Among the 25 ZIKV polymerase chain reactions – negative patients, dengue virus (DENV) lgG antibodies were present in the cerebrospinal fluid of 12 patients and in the serum of 10 patients, and serum DENV lgM test results were positive in 1. These data raise the possibility of primary DENV infection and false-positive ZIKV serologic test results from crossreactivity.
Overall, the study supports the association between ZIKV and the Guillain-Barre syndrome, although confirmation in another cohort would strengthen this assertion. Although high rates of seropositivity may prove protective against further waves of ZIKV-related Guillain-Barre syndrome in Central and South America,the ZIKV pandemic is just beginning in North America and Africa, and an increase in the incidence of the Guillan-Barre syndrome may follow.